The Company and 3SBio Inc. (3SBio) , a China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, on August 23, 2010, completed a Development, Distribution and License Agreement for voclosporin.  Under the terms of the agreement, 3SBio has exclusive rights to all transplant and autoimmune indications of voclosporin in China, including Hong Kong and Taiwan, excluding ophthalmic indications and medical devices.  3SBio will be responsible for the clinical development, registration and commercialization of voclosporin in China.  The Company will also receive ongoing royalties based on sales of voclosporin by 3SBio.  The Company will provide, under separate agreement, commercial supply to 3SBio on a cost-plus basis. 3Sbio is currently in the planning stage of a Chinese Phase 3 kidney transplant clinical trial for the prevention of organ rejection.